Extended Data Fig. 8: Glycolysis/glycogen pathway inhibitors and wound healing.
From: Targeting SLC7A11 improves efferocytosis by dendritic cells and wound healing in diabetes
a, Co-administration of CP-91149 or 3-BP with erastin regimen can reverse the accelerated wound healing in the context of Slc7a11 blockade. Wound healing dynamics of wild-type mice treated with erastin regimen or vehicle regimen consisting of a single administration to the wound site of apoptotic cells at day 0 along with erastin or DMSO vehicle given on day 0 to day 2. When indicated, the compounds CP-91149 and 3-BP were topically administered on the wounds, on day 0 to day 2. Data represent means ± SEM and show one out of two independent experiments with n = 9; DMSO regimen, n = 10; Erastin regimen, n = 8; DMSO regimen + CP-91149 or 3-BP, n = 8; Erastin regimen + CP-91149 or 3-BP (* P < 0.05; **** P < 0.0001 via Two-way ANOVA with Tukey’s multiple comparisons test).
